[{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Immediate Release Soluble Solid Dispersion Tablet","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ribavirin","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Allegro Ophthalmics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch Health","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"Bausch Health \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Bausch Health \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Immediate release tablet","sponsorNew":"Bausch Health \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Eye Drops","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bausch Health \/ Bausch Health Companies","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch Health Companies"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Bausch Health \/ Bausch Health Companies","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch Health Companies"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Bausch health","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Allegro Ophthalmics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch Health","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"Bausch Health \/ Bausch Health Companies","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Bausch Health Companies"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Bausch Health \/ Baush Health","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Baush Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tazarotene","moa":"RAR-alpha","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Bausch Health \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Bausch health","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Salix","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Salix"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Alvogen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch Health \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opoid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Chlordiazepoxide","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ortho Dermatologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Not Applicable"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dental and Oral Health","graph2":"Approved","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"ORAPHARMA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ORAPHARMA \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"ORAPHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dental and Oral Health","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Microspheres, Sustained Release","sponsorNew":"Bausch Health \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Amiselimod HCl","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bausch Health \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bausch Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine indicated for acne vulgaris in patients 12 years of age and older.

                          Brand Name : Cabtreo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 11, 2024

                          Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : CABTREO (clindamycin phosphate, adapalene, benzoyl peroxide) topical gel is a prescription medicine which is now available in US for the topical treatment of acne vulgaris in age 12 years and older.

                          Brand Name : Cabtreo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 30, 2024

                          Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : MT-1303 (amiselimod HCl) is a sphingosine-1-phosphate receptor functional antagonist, which is being evaluated in Phase II clinical trial studies with patients for the treatment of ulcerative colitis.

                          Brand Name : MT-1303

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 21, 2023

                          Lead Product(s) : Amiselimod HCl

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Cabtreo (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel which is indicated for the treatment of Acne Vulgaris in patients twelve years of age and older.

                          Brand Name : Cabtreo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 20, 2023

                          Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Arestin® (minocycline hydrochloride) is a member of the tetracycline class of antibiotics, a bacteriostatic that exerts its antimicrobial activity by inhibiting protein synthesis, in adults with periodontitis.

                          Brand Name : Arestin

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 18, 2023

                          Lead Product(s) : Minocycline Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.

                          Brand Name : Arestin

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 18, 2023

                          Lead Product(s) : Minocycline Hydrochloride

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Approved

                          Recipient : ORAPHARMA

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : IDP-126 (clindamycin 1.2%, adapalene 0.15%, benzoyl peroxide 3.1%) gel has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris by inhibiting bacterial protein synthesis.

                          Brand Name : IDP-126

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 01, 2023

                          Lead Product(s) : Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle™ and Efurix as topical oncological treatments.

                          Brand Name : Limbitrol

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 28, 2022

                          Lead Product(s) : Chlordiazepoxide,Amitriptyline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : MedQuímica Indústria Farmacêutica

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : RELISTOR (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

                          Brand Name : Relistor

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 24, 2022

                          Lead Product(s) : Naltrexone Methobromide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Recipient : Salix Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.

                          Brand Name : Ryaltris

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 23, 2022

                          Lead Product(s) : Olopatadine Hydrochloride,Mometasone Furoate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Glenmark Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank